JP5840498B2 - プロテアーゼ耐性ポリペプチドを選択するための方法 - Google Patents

プロテアーゼ耐性ポリペプチドを選択するための方法 Download PDF

Info

Publication number
JP5840498B2
JP5840498B2 JP2011539034A JP2011539034A JP5840498B2 JP 5840498 B2 JP5840498 B2 JP 5840498B2 JP 2011539034 A JP2011539034 A JP 2011539034A JP 2011539034 A JP2011539034 A JP 2011539034A JP 5840498 B2 JP5840498 B2 JP 5840498B2
Authority
JP
Japan
Prior art keywords
protease
polypeptide
peptide
polypeptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011539034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510803A (ja
JP2012510803A5 (https=
Inventor
キャロライン、エネバー
ローラン、ジェスペル
マルゴルザタ、プペカ
イアン、エム、トムリンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2012510803A publication Critical patent/JP2012510803A/ja
Publication of JP2012510803A5 publication Critical patent/JP2012510803A5/ja
Application granted granted Critical
Publication of JP5840498B2 publication Critical patent/JP5840498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
JP2011539034A 2008-12-05 2009-12-04 プロテアーゼ耐性ポリペプチドを選択するための方法 Active JP5840498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12013508P 2008-12-05 2008-12-05
US61/120,135 2008-12-05
PCT/EP2009/066395 WO2010063818A2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015147120A Division JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Publications (3)

Publication Number Publication Date
JP2012510803A JP2012510803A (ja) 2012-05-17
JP2012510803A5 JP2012510803A5 (https=) 2013-01-31
JP5840498B2 true JP5840498B2 (ja) 2016-01-06

Family

ID=42169477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539034A Active JP5840498B2 (ja) 2008-12-05 2009-12-04 プロテアーゼ耐性ポリペプチドを選択するための方法
JP2015147120A Pending JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015147120A Pending JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Country Status (15)

Country Link
US (3) US8685895B2 (https=)
EP (1) EP2364326B1 (https=)
JP (2) JP5840498B2 (https=)
KR (1) KR101740066B1 (https=)
CN (1) CN102307897B (https=)
AU (1) AU2009324037B2 (https=)
BR (1) BRPI0922772B1 (https=)
CA (1) CA2745448C (https=)
EA (1) EA026508B1 (https=)
ES (1) ES2688621T3 (https=)
IL (1) IL212923A0 (https=)
MX (1) MX2011005874A (https=)
SG (1) SG194383A1 (https=)
WO (1) WO2010063818A2 (https=)
ZA (1) ZA201103575B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012022703A2 (en) * 2010-08-20 2012-02-23 Glaxo Group Limited Improved anti-serum albumin binding variants
JP6210982B2 (ja) * 2012-06-22 2017-10-11 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
CN105658659A (zh) * 2013-07-15 2016-06-08 北卡罗来纳州大学 蛋白酶抗性肽配体
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
JP6766253B2 (ja) * 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
CN113766930B (zh) * 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
US11584781B2 (en) * 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4204460A4 (en) 2020-08-26 2024-09-25 Twist Bioscience Corporation METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU3040101A (en) 2000-02-03 2001-08-14 Domantis Limited Combinatorial protein domains
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
BR122019021416A2 (https=) 2003-09-19 2019-12-21
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
EP2084182B1 (en) * 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2398825B1 (en) * 2009-02-19 2017-10-25 Glaxo Group Limited Single variable domain against serum albumin

Also Published As

Publication number Publication date
JP2015231380A (ja) 2015-12-24
WO2010063818A3 (en) 2010-08-12
US10302655B2 (en) 2019-05-28
US8685895B2 (en) 2014-04-01
KR20110102397A (ko) 2011-09-16
MX2011005874A (es) 2011-06-27
US10466252B2 (en) 2019-11-05
US20140187750A1 (en) 2014-07-03
EA026508B1 (ru) 2017-04-28
CA2745448A1 (en) 2010-06-10
IL212923A0 (en) 2011-07-31
BRPI0922772A2 (en) 2018-11-06
CN102307897B (zh) 2016-01-20
US20110229458A1 (en) 2011-09-22
AU2009324037A1 (en) 2010-06-10
EP2364326B1 (en) 2018-07-04
ZA201103575B (en) 2012-01-25
JP2012510803A (ja) 2012-05-17
ES2688621T3 (es) 2018-11-05
SG194383A1 (en) 2013-11-29
KR101740066B1 (ko) 2017-05-25
CA2745448C (en) 2018-09-18
BRPI0922772B1 (pt) 2021-09-08
US20180088128A1 (en) 2018-03-29
AU2009324037B2 (en) 2015-07-30
CN102307897A (zh) 2012-01-04
EA201170762A1 (ru) 2011-12-30
EP2364326A2 (en) 2011-09-14
WO2010063818A2 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
JP5840498B2 (ja) プロテアーゼ耐性ポリペプチドを選択するための方法
JP5325211B2 (ja) ポリペプチド、抗体可変ドメインおよびアンタゴニスト
KR102469853B1 (ko) 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP2010528645A (ja) プロテアーゼ耐性ポリペプチドを選択する方法
AU2017279662B2 (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20100040840A (ko) 폴리펩티드，항체 가변 도메인 및 길항제
JP2009519011A (ja) インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151111

R150 Certificate of patent or registration of utility model

Ref document number: 5840498

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350